Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.

Journal Article (Journal Article)

UNLABELLED: We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed. CLINICAL TRIALS REGISTRATION: NCT02073656.

Full Text

Duke Authors

Cited Authors

  • Cooper, C; Naggie, S; Saag, M; Yang, JC; Stamm, LM; Dvory-Sobol, H; Han, L; Pang, PS; McHutchison, JG; Dieterich, D; Sulkowski, M

Published Date

  • August 15, 2016

Published In

Volume / Issue

  • 63 / 4

Start / End Page

  • 528 - 531

PubMed ID

  • 27225242

Pubmed Central ID

  • PMC4967607

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

Digital Object Identifier (DOI)

  • 10.1093/cid/ciw349


  • eng

Conference Location

  • United States